THOUSAND OAKS, Calif., May 6 /PRNewswire-FirstCall/ -- Amgen , today announced results of voting at the company's Annual Meeting of Stockholders, held at The St. Regis Hotel, San Francisco, Calif. Approximately 87.3 percent of outstanding shares were represented at the meeting.
The director nominees: David Baltimore, Frank J. Biondi, Jr., Francois de Carbonnel, Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D. Schaeffer and Kevin W. Sharer were each reelected to Amgen's Board of Directors, each receiving a majority of "For" votes of the votes cast. Each was elected by no less than 86.7 percent of the votes cast. With the reelection of these directors, Amgen currently has 12 directors.
With approximately 98.7 percent of "For" votes of the votes cast, stockholders ratified Ernst & Young LLP as Amgen's independent registered public accountants for the year ending Dec. 31, 2009.
Stockholders approved the Amgen 2009 Equity Incentive Plan, which authorizes the issuance of up to 100,000,000 shares of Amgen common stock. The proposal was approved with approximately 81.2 percent of votes cast "For."
Stockholders approved the proposed amendment to the company's Restated Certificate of Incorporation, as amended, to reduce the sixty-six and two-thirds percent (66-2/3%) voting requirement in the company's Restated Certificate of Incorporation, as amended, to a simple majority voting requirement for approval of certain business combinations. Approximately 84.4 percent of the outstanding shares of our common stock were in favor of the amendment.
Stockholders approved a nonbinding resolution recommending that the company amend its Amended and Restated Bylaws, as amended, to permit holders of 10 percent of the company's outstanding common stock the ability to call special meetings. The proposal received approximately 59.5 percent of the votes cast "For" the proposal. Stockholders rejected the proposal requesting that the company change its jurisdiction of incorporation from Delaware to North Dakota. The proposal received less than 3.2 percent of the votes cast "For" the proposal.
The final vote totals will be included in the company's second quarter periodic report to be filed with the Securities and Exchange Commission.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com/.
Contacts: Amgen, Thousand Oaks David Polk: 805-447-4613 (media) Arvind Sood: 805-447-1060 (investors) (Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)
http://photoarchive.ap.org/
PRN Photo Desk, photodesk@prnewswire.com
Amgen
CONTACT: media, David Polk, +1-805-447-4613, or investors, Arvind Sood,
+1-805-447-1060, both of Amgen, Thousand Oaks
Web Site: http://www.amgen.com/
